Please assess the completion status of the following clinical trial:

Trial Title: Single Ascending Dose Study of PCSK-9 Inhibitor (IBI306) in Healthy Subjects.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Chinese healthy men or women aged 18 to 55 years old at screening (inclusive）;~* Serum LDL-C concentration between 1.8 mmol/L and 4.9 mmol/L (inclusive）at screening;~* Body mass index between 19 and 28 kg/m2 (inclusive);~* Willing to maintain the current regular diet and physical activity;~* Female subjects and male subject's partner who could become pregnant should take effective contraceptions during the treatment period and 6 months after dosing;~* Without any medical history of serious diseases;~* Willing to comply with protocol required visit schedule and visit requirements and provide written informed consent.~Exclusion Criteria:~* Breast-feeding or pregnant women;~* History of allergic reaction;~* Previously received any anti-PCSK-9 treatment;~* Vital signs, physical examination, clinical laboratory test, 12-lead ECG, and chest X-ray are abnormal with clinical significance;~* Not willing to stop intense physical activities (such as weight lifting or long-distance running) before 72 hours of the scheduled visits;~* Any hospitalization within one month before screening, or major surgery within six months before screening, or any other unstable medical condition;~* Received an investigational chemical agent within 30 days before dosing；~* Received an investigational biological agent within 90 days before dosing；~* Use of medications including over-the-counter medication within 14 days or less than 5 half-lifes of the agent;~* Use of herb,vitamins or nutraceutical in order to alter serum lipids;~* Positive screen of hepatitis B surface antigen, hepatitis C virus, human immunodeficiency virus or syphilis infection at screening；~* History or clinical evidence of alcohol or drugs of abuse within 12 months before screening;~* With any consumption of alcohol and caffeinated beverages within 72 hours prior to and during the trial;~* Blood donations or blood loss 200 ml and more within 2 months before screening;~* History of organ transplantation or malignant tumor;~* Any conditions which, in the opinion of the Investigator, would make the subject unsuitable for enrollment.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- IBI306 (Type: ACTIVE_COMPARATOR): Subcutaneous or intravenous injection of a single dose of IBI306, dose level according to ascending dose design
- placebo (Type: PLACEBO_COMPARATOR): Subcutaneous or intravenous injection of a single dose of placebo, dose level according to ascending dose design

Based on this trial design, predict the completion outcome and termination type (if applicable).